| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5559111 | NODEN PHARMA | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5559111 (Pediatric) | NODEN PHARMA | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jan, 2019
(5 years ago) | |
| US9023893 | NODEN PHARMA | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
Mar, 2022
(2 years ago) | |
| US8618172 | NODEN PHARMA | Galenical formulations of organic compounds |
Jul, 2028
(4 years from now) | |
Tekturna Hct is owned by Noden Pharma.
Tekturna Hct contains Aliskiren Hemifumarate; Hydrochlorothiazide.
Tekturna Hct has a total of 4 drug patents out of which 3 drug patents have expired.
Expired drug patents of Tekturna Hct are:
- US5559111*PED
- US9023893
- US5559111
Tekturna Hct was authorised for market use on 18 January, 2008.
Tekturna Hct is available in tablet;oral dosage forms.
Tekturna Hct can be used as treatment of hypertension.
Drug patent challenges can be filed against Tekturna Hct from 06 March, 2011.
The generics of Tekturna Hct are possible to be released after 13 July, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Indication(I-600) | Jul 16, 2012 |
Drugs and Companies using ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE ingredient
NCE-1 date: 06 March, 2011
Market Authorisation Date: 18 January, 2008
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
TEKTURNA HCT family patents
